Melatonin Studied for Prevention Of Delirium in Elderly Patients
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Back to table of contents Previous article Next article Clinical & ResearchFull AccessMelatonin Studied for Prevention Of Delirium in Elderly PatientsJoan Arehart-TreichelJoan Arehart-TreichelPublished Online:31 Mar 2014https://doi.org/10.1176/appi.pn.2014.4a1AbstractNew evidence suggests that low levels of the hormone melatonin are implicated in delirium and that giving melatonin or a melatonin agonist may help prevent delirium.Delirium is a state of disturbed consciousness that often afflicts elderly, hospitalized patients and is associated with risks such as dementia or death. There is no Food and Drug Administration (FDA) approved medication for preventing it.Studies have suggested that low levels of the pineal hormone melatonin might play a role in delirium. Indeed, low melatonin concentrations have been linked with delirium, and melatonin levels tend to decline considerably with aging. One study of this hypothesis, reported in 2011 in the International Journal of Geriatric Psychiatry, was conducted by Tareef Al-Aama, M.D., an internist and geriatrician at King Abdulaziz University in Saudi Arabia, and Canadian colleagues. Their randomized, double-blind, placebo-controlled study of elderly hospitalized patients suggested that melatonin might help prevent delirium. Only 12 percent of their study group getting melatonin experienced delirium, whereas 31 percent of a placebo group did—a significant difference.Now Kotaro Hatta, M.D., Ph.D., a psychiatrist at Juntendo University in Japan, and coworkers have conducted a randomized, rater-blinded, placebo-controlled study of 67 older hospitalized patients to see whether a melatonin agonist called ramelteon might be able to prevent delirium.Their results were encouraging. Only 3 percent of subjects getting ramelteon developed delirium, while 32 percent of subjects receiving a placebo did—a significant difference. These findings were published online February 19 in JAMA Psychiatry."This is an interesting study despite the small size of the sample," Gary Kennedy, M.D., a professor of psychiatry at Albert Einstein College of Medicine and director of the Division of Geriatric Psychiatry at Montefiore Medical Center, told Psychiatric News. "It reinforces the novel theory that melatonin is involved in the genesis of delirium and would explain in part why older adults are more likely to develop delirium. The potential of Ramelteon to reduce the risk of delirium is especially appealing because of its low profile of adverse reactions, unlike the antipsychotics that are so often used when delirious behavior threatens the patient's well-being.""Delirium is a common condition among the elderly patients who are admitted to hospitals, with profound and devastating effects on patients, families, health care systems, and society," Al-Aama told Psychiatric News. "It's quite frustrating that it remains poorly understood in spite of advancement in research and medical knowledge. There has been more interest lately in looking for a role for melatonin disturbance in the formation and therefore the prevention and treatment of delirium, in a 'thinking outside the box' kind of way. This study adds to the body of evidence that melatonin may indeed have a role in delirium. Melatonin and melatonin agonists are appealing as they tend to be reasonably safe and not so expensive. More and larger studies may be needed to confirm its role. But for now, we do seem to be moving in the right direction in fighting delirium."Ramelteon has been approved by the FDA for treating insomnia, Hatta and his team noted, but whether its sleep-promoting ability is related to its delirium-preventing ability is unclear, they said.The study by Hatta and his group was funded by the Japan Society for the Promotion of Science. ■An abstract of "Preventive Effects of Ramelteon on Delirium" can be accessed here. ISSUES NewArchived
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle